BWA
ALNY icon

BDO Wealth Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

BDO Wealth Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5
Closed -$1K – 864
2020
Q2 		$1K Hold
5
– – ﹤0.01% 649
2020
Q1 		$1K Buy
+5
New +$577 ﹤0.01% 694

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BDO Wealth Advisors's ALNY Position: Q3 2020 in Review

BDO Wealth Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2020, closing a stake of 5 shares — an estimated $1K sold.

BDO Wealth Advisors first reported a position in ALNY in Q1 2020 and held it in 2 quarters. The position peaked at $1K in Q2 2020. 356 funds tracked by Wall St. Rank hold ALNY as of Q3 2020.

  • BDO Wealth Advisors reported no remaining Alnylam Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • BDO Wealth Advisors sold 5 Alnylam Pharmaceuticals shares in Q3 2020, an estimated $1K.
  • BDO Wealth Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2020 and held it in 2 quarters.
  • BDO Wealth Advisors's Alnylam Pharmaceuticals position peaked at $1K in Q2 2020.
  • 356 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2020.

Based on BDO Wealth Advisors's 13F filing for Q3 2020, filed 12 Nov 2020.